When it comes to prescribing drugs and evaluating patients for potential drug interactions, PGx testing is no longer a future consideration.

The American Medical Association advocates that physicians become familiar with genetic variations that may affect patients’ drug metabolism and be able to recognize when testing should be used to inform prescribing.

The U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada currently require or recommend testing for more than 60 drugs.

A report from the U.S. Department of Health and Human Services states: “Pharmacogenetic testing for potential ADEs and ineffective drug responses may reduce health care costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treatment and avoidable ADEs.”

Each year in the United States, more than 2.2 million ADEs occur, resulting in more than 100,000 deaths and placing an enormous financial burden on the healthcare system. [2] Genelex has been a trailblazer in the area of genetic testing – focused, innovative, and driven to prevent ADEs.

At our fingertips, we have access to the tools essential for precision prescribing — allowing for personalizing medication decisions whenever they are made.